AnaCardio 🇸🇪
Stockholm biotech developing an oral drug for advanced heart failure
About AnaCardio
AnaCardio AB is developing novel drugs aimed at treating heart failure, specifically targeting impaired contractility through a unique mechanism based on ghrelin signaling. Their lead program involves a first-in-class calcium sensitizing inotrope designed to enhance cardiomyocyte contractility without increasing oxygen consumption or mortality.
AnaCardio is a Sweden-based company founded in 2017, now around 23 people. It has raised $147.5M in disclosed funding, starting with a Series A in 2022. FundFinder classes it as Health & Bio.
Founder: Lars Lund (Founder; Duke University School of Medicine).
Company facts from Harmonic and public filings; team backgrounds from public profiles. Refreshed weekly.
Series B · €62.5M · Oct 2026
Novo Holdings- Novo Holdings — Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation, one of the world’s largest philanthropic enterprise foundations. · cheques £5M – £50M
Series B · €62.5M · Sep 2026
Funding history
● rounds tracked in this directory · ○ earlier rounds web-verified from public announcements. Amounts as announced; undisclosed rounds omitted.